Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regimen Transition After Short-Term Intensive Insulin Therapy in T2DM
NCT07173712Phase 4Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of insulin glargine + lixisenatide, insulin degludec + insulin aspart, insulin glargine in type 2 diabetes mellitus (T2DM). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
insulin glargine + lixisenatideinsulin degludec + insulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07173712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173712.